Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annexon Biosciences (ANNX)
NASDAQ:ANNX
Holding ANNX?
Track your performance easily
ANNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.27 - $8.40
Previous Close$5.16
Volume958.03K
Average Volume (3M)1.30M
Market Cap
$601.17M
Enterprise Value$271.49M
Total Cash (Recent Filing)$340.12M
Total Debt (Recent Filing)$29.61M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Mar 20, 2025EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding106,593,505
10 Day Avg. Volume1,294,894
30 Day Avg. Volume1,302,391
Standard Deviation0.26
R-Squared0.05
Alpha-0.00015
Financial Highlights & Ratios
Price to Book (P/B)1.66
Price to Sales (P/S)363.75
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue169.68
Enterprise Value/Gross Profit135.75
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$17.25Price Target Upside223.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Annexon Biosciences News
PremiumCompany Announcements
Annexon Biosciences Reports Q3 Financial Results
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ANNX FAQ
What was Annexon Biosciences’s price range in the past 12 months?
Annexon Biosciences lowest stock price was $2.27 and its highest was $8.40 in the past 12 months.
What is Annexon Biosciences’s market cap?
Currently, no data Available
When is Annexon Biosciences’s upcoming earnings report date?
Annexon Biosciences’s upcoming earnings report date is Mar 20, 2025 which is in 119 days.
How were Annexon Biosciences’s earnings last quarter?
Annexon Biosciences released its earnings results on Nov 14, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.258 by $0.008.
Is Annexon Biosciences overvalued?
According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued.
Does Annexon Biosciences pay dividends?
Annexon Biosciences does not currently pay dividends.
What is Annexon Biosciences’s EPS estimate?
Annexon Biosciences’s EPS estimate is -$0.27.
How many shares outstanding does Annexon Biosciences have?
Annexon Biosciences has 106,593,506 shares outstanding.
What happened to Annexon Biosciences’s price movement after its last earnings report?
Annexon Biosciences reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.258. Following the earnings report the stock price went down -3.359%.
Which hedge fund is a major shareholder of Annexon Biosciences?
Among the largest hedge funds holding Annexon Biosciences’s share is Woodline Partners LP. It holds Annexon Biosciences’s shares valued at 20M.
---
Annexon Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.25 (223.64% Upside)
$17.25 (223.64% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-48.12%
Trailing 12-Months
Asset Growth
85.84%
Trailing 12-Months
Company Description
Annexon Biosciences
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005; ANX007; and ANX009.
---
ANNX Stock 12 Month Forecast
Average Price Target
$17.25
▲(223.64% Upside)
Technical Analysis
Best Analysts Covering ANNX
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+20.75%
reiterated a buy rating 7 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +20.75% per trade.
---